"INO has had a number of successes clinically and marquee collaborations that have led to its market cap being what it is today." (5/20/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Ross Silver More >
"Subsequent analysis of CANF's CF101 data shows promise in a certain subset of patients." (5/13/15) Can-Fite BioPharma Ltd. - The Life Sciences Report 2015 Small-Cap Biotech Watchlist Update with Reni Benjamin More >
The Life Sciences Report Biotech Watchlist Portfolio Tracker
It has been a boom year for biotechs, and most of the companies on The Life Sciences Report's Biotech Watchlist 2013 have risen with the proverbial tide. The Watchlist companies were selected by industry experts based on a variety of factors, including sound science, good management, therapy area and catalysts keyed to the drug development process. We have been tracking the companies throughout the year: With our new Portfolio Tracker, it is now easy for Life Science Report readers to do the same.
October 2013 Biotech Watchlist Update
January 2013 Biotech Watchlist
April 2013 Biotech Watchlist Update
How Are They Doing? Update on the Progress of Expert Picks
The Approval Process in Action (infographic)
The chart below shows stock prices for the 17 companies on the 2013 Biotech Watchlist. The heavy green line shows the average gain/loss of the portfolio as a whole. Portfolio average change year-to-date is [loading].
About These Individual Charts
The Yahoo finance charts provided below are updated in real time and show stock prices for each company for the year to date. Time spans for catalysts identified by Biotech Watchlist analysts are lighted in green.
"We view Omidria sales as a means for OMER to fund one of the most exciting biotechnology pipelines in the industry." (4/8/15) Omeros Corp. - The Life Sciences Report Interview with Jason Kolbert More >